Home > News > Lumiphore and Echelon Biosciences Introduce Novel Cancer Assays
April 4th, 2006
Lumiphore and Echelon Biosciences Introduce Novel Cancer Assays
Abstract:
Lumiphore Inc. and Echelon Biosciences Inc. jointly announce the finalization of a license agreement that provides Echelon access to Lumiphore's proprietary lanthanide-complex technology for the development of TR-FRET assays and reagents for use in research and drug discovery in the field of phospholipid signaling and lipid-protein interactions.
Source:
prnewswire
| Related Links |
| Related News Press |
Nanomedicine
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
UC Irvine physicists discover method to reverse ‘quantum scrambling’ : The work addresses the problem of information loss in quantum computing system April 17th, 2026
|
|
||
|
|
||
| The latest news from around the world, FREE | ||
|
|
||
|
|
||
| Premium Products | ||
|
|
||
|
Only the news you want to read!
Learn More |
||
|
|
||
|
Full-service, expert consulting
Learn More |
||
|
|
||